Angiographic findings in patients with refractory unstable angina according to troponin T status.

BACKGROUND The CAPTURE (C7E3 fab AntiPlatelet Therapy in Unstable REfactory angina) trial enrolled patients with refractory unstable angina and documented a therapeutic benefit for abciximab, a platelet glycoprotein IIb/IIIa receptor antagonist, that was particularly evident in patients with elevated troponin T (TnT) levels. In the current study, we related the angiographic data to the TnT status of the CAPTURE patients. METHODS AND RESULTS In 853 patients, angiographic data at baseline and 18 to 24 hours after treatment were available and assessed by an Angiographic Committee with respect to TIMI flow, lesion severity, and visibility of thrombus. TnT levels >0.1 microg/L were found in 30.9% of the patients. Before randomization, thrombus was visible in 14.6% of TnT-positive patients (TnT levels >0.1 microg/L) and 4.2% of TnT-negative patients (P=0.004). Complex lesion characteristics B2+/C (72.0% versus 53.9%; P<0.001) and TIMI flow <2 (15.6% versus 5. 1%; P<0.001) were more frequent in TnT-positive patients. Abciximab was effective with respect to reduction of visible thrombus, increase of TIMI flow, and reduction of cardiac events in TnT-positive patients only. Multivariate analysis identified TnT status, but not angiographic findings, as an independent predictor for both outcome and efficacy of treatment with abciximab. CONCLUSIONS Complex lesion characteristics and visible thrombus formation at baseline were significantly linked to TnT elevation. However, TnT status was a more powerful predictor of increased cardiac risk and efficacy of treatment with abciximab than either. Relative to the angiogram, TnT can thus be considered a more sensitive marker for the underlying pathology, identifying patients with unstable angina who will particularly benefit from antiplatelet treatment.

[1]  Ric,et al.  CARDIAC TROPONIN T LEVELS FOR RISK STRATIFICATION IN ACUTE MYOCARDIAL ISCHEMIA , 2000 .

[2]  C. Heeschen,et al.  Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. , 1999, The New England journal of medicine.

[3]  David P Miller,et al.  Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Block , 1998, Journal of the American College of Cardiology.

[4]  T. Meinertz,et al.  Enhanced coagulation activation in troponin T-positive unstable angina pectoris. , 1998, American heart journal.

[5]  R. Califf,et al.  Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. , 1998, Journal of the American College of Cardiology.

[6]  C. Heeschen,et al.  Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. , 1997, The New England journal of medicine.

[7]  K. Thygesen,et al.  Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia. , 1997, Circulation.

[8]  L. Wallentin,et al.  Noninvasive risk stratification in unstable coronary artery disease: exercise test and biochemical markers. FRISC Study Group. , 1997, The American journal of cardiology.

[9]  M. Riggs,et al.  Usefulness of positive troponin-T and negative creatine kinase levels in identifying high-risk patients with unstable angina pectoris. , 1997, The American journal of cardiology.

[10]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[11]  M. Davies.  The composition of coronary-artery plaques. , 1997, The New England journal of medicine.

[12]  R. Virmani,et al.  Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. , 1996, Circulation.

[13]  V. Gökhan Cin,et al.  The prognostic value of serum troponin T in unstable angina. , 1996, International journal of cardiology.

[14]  P. Teirstein,et al.  Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. , 1996, Circulation.

[15]  D. Waters,et al.  Prognostic value of cardiac troponin T in unstable angina pectoris. , 1995, The American journal of cardiology.

[16]  K. Thygesen,et al.  Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction. Analysis of 28 months of follow-up in 196 patients. , 1995, Journal of the American College of Cardiology.

[17]  Daniel B. Mark,et al.  Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. , 1994, Circulation.

[18]  W. Roberts,et al.  Coronary arteries in unstable angina pectoris, acute myocardial infarction, and sudden coronary death. , 1994, American heart journal.

[19]  A. Remppis,et al.  Development and in vitro characterization of a new immunoassay of cardiac troponin T. , 1992, Clinical chemistry.

[20]  D. Waters,et al.  Quantitative Angiographic Morphology of the Coronary Artery Lesions at Risk of Thrombotic Occlusion , 1992, Circulation.

[21]  W. Roberts,et al.  Morphologic comparison of frequency and types of acute lesions in the major epicardial coronary arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction. , 1991, Journal of the American College of Cardiology.

[22]  H. Katus,et al.  S-troponin T in suspected ischemic myocardial injury compared with mass and catalytic concentrations of S-creatine kinase isoenzyme MB. , 1991, Clinical chemistry.

[23]  A. Remppis,et al.  Diagnostic Efficiency of Troponin T Measurements in Acute Myocardial Infarction , 1991, Circulation.

[24]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[25]  G. Vetrovec,et al.  Angiographic observations and clinical relevance of coronary thrombus in unstable angina pectoris. , 1989, The American journal of cardiology.

[26]  David W. Hosmer,et al.  Best subsets logistic regression , 1989 .

[27]  F. Harrell,et al.  Regression models in clinical studies: determining relationships between predictors and response. , 1988, Journal of the National Cancer Institute.

[28]  M. Davies,et al.  Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. , 1986, Circulation.

[29]  E. Falk.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.